Intercell Ag

Valneva Austria Gmbh

André Habel

Michael Buschle

Frank Mattner

Karen Lingnau

Karin Prinz

Frédéric Tangy

Walter G Schmidt

Wolfgang Zauner

Christoph Klade

Oresta Vytvytska

Jörg Fritz

Jörge Fritz

Alexander Otava

Sandra Zinke

Helen Kirlappos

Samantha Brandler

Joerg Fritz

Philippe Despres

Jörg Faculty Of Medicine Department Of Immunology Fritz

The invention refers an improved vaccine against infections with pathogens, especially viral pathogens, comprising an antigen, a peptide of the formula R&#x2014;XZSZ&#x2014;XZX&#x2014;Rand an immunostimulatory deoxynucleic acid containing deoxyinosine and/or deoxyuridine residues.

Vaccines comprising an immunostimulatory peptide and an immunostimulatory oligodeoxynucleic acid molecule

The invention refers to an improved vaccine against infections with pathogens, especially viral pathogens, comprising an antigen, a peptide of the formula R&#x2014;XZXZ-XZX&#x2014;Rand an immunostimulatory deoxynucleic acid containing deoxyinosine and/or deoxyuridine residues.

Vaccines

The invention discloses polypeptides encoded by an alternative reading frame of a pathogenic virus, which polypeptides&#x2014;start with a methionine amino acid residue,&#x2014;comprise an antigenic determinant and&#x2014;comprise more than 7 amino acid residues and fragments of said polypeptides comprising more than 7 amino acids.

Antigens encoded by alternative reading frames from pathogenic viruses

Described is a method for isolating Hepatitis C Virus peptides (HPs) which have a binding capacity to a MHC/HLA molecule or a complex comprising said HCV-peptide and said MHC/HLA molecule characterized by the following steps: &#x2014;providing a pool of HCV-peptide, said pool containing HCV-peptides which bind to said MHC/HLA molecule and HCV-peptides which do not bind to said MHC/HLA molecule, &#x2014;contacting said MHC/HLA molecule with said pool of HCV-peptides whereby a HCV-peptide which has a binding capacity to said MHC/HLA molecule binds to said MHC/HLA molecule and a complex comprising said HCV-peptide and said MHC/HLA molecule is formed, &#x2014;detecting and optionally separating said complex from the HCV-peptide which do not bind to said MHC/HLA molecule and optionally isolating and characterizing the HCV-peptide from said complex.

Method for isolating hepatitis C virus peptides

Growing community of inventors

Vienna, Austria

André Habel